Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03212170 | FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer | completed | Phase 2 | 21 | University of Wisconsin, MadisonOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT03345420 | Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer(NOVEMBER) | completed | Phase 2 | 102 | University of UtahOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT05963984 | A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants(SUMIT-BC) | completed | Phase 2 | 60 | Carrick Therapeutics LimitedINDUSTRY | 5 | Dec 26, 2025 | clinicaltrials |
| NCT06570811 | Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients | completed | Phase 2 | 40 | Damanhour UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT03095352 | Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease | completed | Phase 2 | 76 | Laura Huppert, MD, BAOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT02760030 | Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 14 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05001347 | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | completed | Phase 2 | 25 | I-Mab Biopharma US LimitedINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT03310957 | Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer | completed | Phase 1 / Phase 2 | 185 | Seagen Inc.INDUSTRY | 4 | Dec 12, 2025 | clinicaltrials |
| NCT02783690 | A Trial of 15 Fraction vs 25 Fraction Pencil Beam Scanning Proton Radiotherapy After Mastectomy in Patients Requiring Regional Nodal Irradiation | completed | Phase 2 | 88 | Mayo ClinicOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05520723 | Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED(PRIMED) | completed | Phase 2 | 50 | MedSIROTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT05190770 | A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer | completed | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05383170 | A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers(Catalyst) | completed | Phase 1 / Phase 2 | 6 | Cytovation ASINDUSTRY | 5 | Nov 28, 2025 | clinicaltrials |
| NCT01147965 | QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA | completed | Phase 1 / Phase 2 | 43 | NantCell, Inc.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT01373710 | Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous Meningitis(HIT) | completed | Phase 1 / Phase 2 | 34 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT01975142 | Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment. | completed | Phase 2 | 155 | Institut CurieOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT02593175 | Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC | completed | Phase 2 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03620643 | Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours(ROLo) | completed | Phase 2 | 33 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT03822468 | Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer(AMALEE) | completed | Phase 2 | 376 | Novartis PharmaceuticalsINDUSTRY | 23 | Oct 16, 2025 | clinicaltrials |
| NCT01982448 | Cisplatin vs Paclitaxel for Triple Negative Breast Cancer | completed | Phase 2 | 147 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT02958852 | A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer(ABC-SE) | completed | Phase 2 | 126 | Lund University HospitalOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT02007512 | Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer | completed | Phase 2 | 247 | PfizerINDUSTRY | 7 | Sep 2, 2025 | clinicaltrials |
| NCT03093350 | TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer(TACTIC) | completed | Phase 2 | 12 | Baylor College of MedicineOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05549505 | A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery | completed | Phase 2 | 152 | Arvinas Inc.INDUSTRY | 4 | Aug 29, 2025 | clinicaltrials |
| NCT07143097 | Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer | completed | Phase 2 | 80 | Beni-Suef UniversityOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT04862585 | Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel | completed | Phase 2 / Phase 3 | 130 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT05259696 | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)(GLIMMER-01) | completed | Phase 1 / Phase 2 | 69 | Palleon Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT01149083 | Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer | completed | Phase 2 | 77 | National Cancer Institute (NCI)NIH | 2 | Aug 15, 2025 | clinicaltrials |
| NCT04300790 | Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients(METALLICA) | completed | Phase 2 | 69 | MedSIROTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT05417451 | Multi-Omics Study of the Effect and Mechanisms of Acupuncture on Psychoneurological Symptoms Among Breast Cancer Survivors | completed | Phase 2 | 46 | University of Illinois at ChicagoOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07081581 | Analgesic Effect of Serratus Plane Block With Adjuvant Agents in Breast Cancer Surgery | completed | Phase 2 | 75 | Sultan Abdulhamid Han Training and Research Hospital, Istanbul, TurkeyOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT03755141 | Efficacy and Safety of Trastuzumab Biosimilar (Herzuma®) Plus Treatment of Physician's Choice (TPC) in Patients With HER-2 Positive Metastatic Breast Cancer | completed | Phase 2 | 109 | National Cancer Center, KoreaOTHER_GOV | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05632848 | Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients | completed | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Jul 21, 2025 | clinicaltrials |
| NCT04352777 | Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer | completed | Phase 2 | 18 | Duke UniversityOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06355024 | Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer | completed | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT04290897 | Oxaloacetate for the Improvement of Cognitive Complaints in Stage 0-IIIA Breast Cancer Survivors | completed | Phase 2 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT03106415 | Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 23 | Mayo ClinicOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT03094052 | Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib | completed | Phase 2 | 11 | University of California, San FranciscoOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04420598 | DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease(DEBBRAH) | completed | Phase 2 | 41 | MedSIROTHER | 2 | Jun 24, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT03222856 | Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes(KELLY) | completed | Phase 2 | 44 | MedSIROTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT02142959 | RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE | completed | Phase 2 | 187 | BiogenINDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT01441947 | Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer | completed | Phase 2 | 68 | Massachusetts General HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT05054374 | A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer | completed | Phase 1 / Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT03188393 | Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery | completed | Phase 2 | 105 | NRG OncologyOTHER | 2 | May 22, 2025 | clinicaltrials |
| NCT04754399 | Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias | completed | Phase 2 | 40 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT01818063 | Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer | completed | Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT02040857 | Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer | completed | Phase 2 | 162 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT03219476 | Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer | completed | Phase 2 | 37 | Medical College of WisconsinOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT01349959 | Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer | completed | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Apr 27, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jan 2, 2026source: clinicaltrials